Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

142.04USD
19 Oct 2017
Change (% chg)

$1.36 (+0.97%)
Prev Close
$140.68
Open
$140.79
Day's High
$142.97
Day's Low
$140.75
Volume
2,625,152
Avg. Vol
1,815,086
52-wk High
$142.97
52-wk Low
$109.32

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $357,562.41
Shares Outstanding(Mil.): 2,684.00
Dividend: 0.84
Yield (%): 2.52

Financials

  Industry Sector
P/E (TTM): -- 30.44 16.24
EPS (TTM): -- -- --
ROI: -- 14.17 10.90
ROE: -- 15.52 14.09

BRIEF-Arcturus Therapeutics to collaborate with Johnson & Johnson

* Arcturus Therapeutics announces strategic collaboration with Johnson & Johnson Innovation to discover and develop RNA medicines

19 Oct 2017

BRIEF-J&J sets quarterly cash dividend of $0.84 per share

* Sets quarterly cash dividend of $0.84 per share Source text for Eikon: Further company coverage:

19 Oct 2017

BRIEF-‍Johnson & Johnson Medical GmbH to acquire Surgical Process Institute​

* ‍johnson & Johnson Medical Devices Companies says definitive agreement to acquire German software company, Surgical Process Institute​

19 Oct 2017

Johnson & Johnson wins reversal of $72 million verdict over talc cancer risks

Johnson & Johnson on Tuesday won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company's talc-based products like Johnson's Baby Powder.

17 Oct 2017

UPDATE 2-J&J wins reversal of $72 mln verdict over talc cancer risks

Oct 17 Johnson & Johnson on Tuesday won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company's talc-based products like Johnson's Baby Powder.

17 Oct 2017

New cancer drugs help Johnson & Johnson top profit estimates

Johnson & Johnson posted better-than-expected third-quarter earnings, raising its full-year forecast due to growth from new cancer drugs and high-margin treatments picked up in its $30 billion acquisition of Actelion earlier this year.

17 Oct 2017

UPDATE 5-New cancer drugs help J&J top profit estimates

* Shares rise 2.4 pct (Adds detail about talc verdict in last paragraph)

17 Oct 2017

J&J wins reversal of $72 million verdict over talc cancer risks

Oct 17 Johnson & Johnson on Tuesday won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company's talc-based products like Johnson's Baby Powder.

17 Oct 2017

US STOCKS SNAPSHOT-Dow cracks 23,000 mark for the first time

Oct 17 The Dow Industrials breached the 23,000 mark for the first time on Tuesday, helped by a rally in shares of UnitedHealth and Johnson & Johnson.

17 Oct 2017

J&J's Puerto Rico plants running, can't rule out shortages

NEW YORK Johnson & Johnson said all of its manufacturing sites on Puerto Rico are running again after Hurricane Maria hit the island last month, but it cannot rule out intermittent shortages of some of its drugs.

17 Oct 2017

Earnings vs. Estimates